Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 722008 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
Electronic (PDF)Add to Basket
1 - 5 UsersAdd to Basket
Site LicenseAdd to Basket
EnterprisewideAdd to Basket



Business Strategies Of Pharma Makers From Central And Eastern Europe 2007 - Acquisition Prospects And Development Forecasts
PMR Ltd, Dec 2007, Pages: 111


  Description  
  Table of Contents  
  Summary  
  Companies Mentioned  
    
   
 Enquire before Buying  
 Send to a Friend  

The report Business strategies of pharma makers from Central and Eastern Europe 2007 from PMR profiles the most prospective indigenous pharmaceutical manufacturers in Central and Eastern European (CEE) countries. As potential acquisition targets for both multinationals and regional players, a critical examination of their performance and growth strategies, from operations to branding, provides invaluable intelligence necessary in a rapidly developing market.

These companies including Gedeon Richter, Krka, Polpharma, Sanitas and Zentiva are on the brink of next phase development, either through acquisition of smaller firms or merger with larger organisations. With a dynamically changing market regionally and globally, this report performs essential analysis on their various strengths, weaknesses, opportunities and threats.

Key Research:

- Major regional producers, which have yet to fall into the hands of larger rivals, include Krka, Sanitas and Zentiva.
- Producers in EU’s newest markets, such as Russia, Ukraine, and ex-Soviet bloc countries, are catching the eye.
- In the short term, perhaps the strongest impact will be made by competitors from India and China.
- In 2007, there has been an increased activity of foreign players in Romania and Bulgaria.
- Russia’s drug market is expected to double by 2020.
- Consolidation continues to be a major trend for CEE market development.

An essential read for:

- top managers, strategic planners and executives of companies considering entry or active in or interested in entering the Central and Eastern European market
- companies engaged in manufacturing, distributing and importing pharmaceuticals
- key decision makers and consultants involved in the healthcare industry
- multinational giants interested in acquisition within Central and Eastern Europe and potential competitors in the region
- regional players investigating successful growth strategies of their competitors or looking to be acquired.

This report is an invaluable resource for any company considering merger and acquisitions in the Central and Eastern European healthcare and pharmaceuticals market.

A Word from the Author

Central and Eastern Europe has been a field of intensive merger and acquisition activity over the last few years. One example is the recent merger of two regional powers: Gedeon Richter and Polpharma, which are likely to become the largest player in this part of Europe. Not only will the deal strengthen their already strong positions on their domestic markets - Hungary and Poland – but it will affect their operations on foreign markets, especially Russia, due to Richter's acquisition of Akrihin, controlled by Polpharma.

Regional drug makers such as Krka, Zentiva and Sanitas, as well as the abovementioned two, offer benefits such as greater economies of scale, low manufacturing costs and high margin export trade potential, not to mention large scale penetration of a healthily growing marketplace to investors.

On the other hand, emerging markets of the CEE region still offer potential investors very attractive acquisition targets that should increasingly come under the gaze of the foreign investors in the coming years, such as Antibiotice in Romania; Pharmstandart, Otechesvennye Lekarstva and Pharm-Centr in Russia; and Darnitsa, Arterium and Farmak in Ukraine.

Joanna Swatowska-Rybak, Head Pharmaceutical Market Analyst


Customers who bought this item also bought

OTC market in Central and Eastern Europe 2009: Comparative analysis and development forecasts for 2009-2011

Gedeon Richter Generics Company Intelligence Report

Internationalisation Strategies of CEE Retailers

Premium Company Profile Gedeon Richter

Retailers’ Strategies in Central and Eastern Europe 2008: Market Analysis and Development Forecasts

Telecoms Market in Central and Eastern Europe 2007 Development Forecasts 2007-2010

Central and Eastern European (CEE) Conferencing Services - A Market Insight

Injection Molding Of Packaging and Mass Products In The CEE Region

The Pharmaceutical Market: Hungary

Pharmaceutical Contract Manufacturing and API Sourcing In Central and Eastern Europe 2009

Central & Eastern Europe (CEE) Logistics Report 2004

OTC Market in Central and Eastern Europe 2008: Comparative Analysis and Development Forecasts for 2008-2010



Top of page


   All rights reserved. © Copyright 2009 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds